{"id":4207,"date":"2024-01-30T15:02:35","date_gmt":"2024-01-30T14:02:35","guid":{"rendered":"http:\/\/blog.lallianse.com\/?p=4207"},"modified":"2024-10-16T11:40:51","modified_gmt":"2024-10-16T09:40:51","slug":"success-story-biomunex-pharmaceuticals-2","status":"publish","type":"post","link":"https:\/\/blog.lallianse.com\/index.php\/en\/success-story-biomunex-pharmaceuticals-2\/","title":{"rendered":"Success story : Biomunex Pharmaceuticals"},"content":{"rendered":"\n<h2 class=\"has-text-color has-medium-font-size wp-block-heading\" style=\"color:#d1b04c\"><strong>January 2024<\/strong><\/h2>\n\n\n\n<p class=\"has-text-color\" style=\"color:#546a7b\">A few months ago, in one of the last <strong><a rel=\"noreferrer noopener\" href=\"http:\/\/blog.lallianse.com\/index.php\/en\/2023\/03\/22\/do-you-speak-lallianse-19-pierre-emmanuel-gerard-biomunex-2\/\" target=\"_blank\">DYSL<\/a> <\/strong><a rel=\"noreferrer noopener\" href=\"https:\/\/www.linkedin.com\/in\/ACoAAAFrnjgBWsYa1udPVi-g2Q7FqrVbL4_phaA\" target=\"_blank\">Pierre-Emmanuel Gerard<\/a>, presented the key issues of <a rel=\"noreferrer noopener\" href=\"https:\/\/www.linkedin.com\/company\/biomunex-pharmaceuticals\/\" target=\"_blank\">BIOMUNEX PHARMACEUTICALS<\/a>.<\/p>\n\n\n\n<p class=\"has-text-color\" style=\"color:#546a7b\">Very happy to share today this excellente news for the development of #Biomunex. <\/p>\n\n\n\n<p class=\"has-text-color\" style=\"color:#546a7b\">For more than 5 years, with one of our key Expert-in-Residence, <a href=\"https:\/\/www.linkedin.com\/company\/11090258\/admin\/feed\/posts\/#\">St\u00e9phane MILOT<\/a>, with <a href=\"https:\/\/www.linkedin.com\/company\/11090258\/admin\/feed\/posts\/#\">Lo\u00efc MOULARD<\/a> also for a few months, at the helm of the outsourced Financial Department, as well as our support around different strategic and operational perspectives, #LallianSe is pleased to contribute to the success of Biomunex.<\/p>\n\n\n\n<p class=\"has-text-color\" style=\"color:#546a7b\">Congratulations to the entire team for starting this clinical study ! \ud83d\udc4f<br><br>Find out more\ud83d\udc49 <a rel=\"noreferrer noopener\" href=\"https:\/\/lnkd.in\/eH47-xeJ\" target=\"_blank\">https:\/\/lnkd.in\/eH47-xeJ<\/a><\/p>\n\n\n\n<p class=\"has-text-color\" style=\"color:#546a7b\"><strong>#Partnership <\/strong><a rel=\"noreferrer noopener\" href=\"https:\/\/www.linkedin.com\/feed\/hashtag\/?keywords=innovation&amp;highlightedUpdateUrns=urn%3Ali%3Aactivity%3A7044351134274060288\" target=\"_blank\">#innovation<\/a> #biotech <a rel=\"noreferrer noopener\" href=\"https:\/\/www.linkedin.com\/feed\/hashtag\/?keywords=healthcare&amp;highlightedUpdateUrns=urn%3Ali%3Aactivity%3A7044351134274060288\" target=\"_blank\">#healthcare<\/a> <a rel=\"noreferrer noopener\" href=\"https:\/\/www.linkedin.com\/feed\/hashtag\/?keywords=immunoth%C3%A9rapie&amp;highlightedUpdateUrns=urn%3Ali%3Aactivity%3A7044351134274060288\" target=\"_blank\">#immunotherapy<\/a> <a rel=\"noreferrer noopener\" href=\"https:\/\/www.linkedin.com\/feed\/hashtag\/?keywords=xir&amp;highlightedUpdateUrns=urn%3Ali%3Aactivity%3A7044351134274060288\" target=\"_blank\">#XIR<\/a><\/p>\n\n\n\n<iframe loading=\"lazy\" src=\"https:\/\/www.linkedin.com\/embed\/feed\/update\/urn:li:share:7155830032945278976\" height=\"652\" width=\"504\" frameborder=\"0\" allowfullscreen=\"\" title=\"Post int\u00e9gr\u00e9\"><\/iframe>\n","protected":false},"excerpt":{"rendered":"<p>January 2024 A few months ago, in one of the last DYSL Pierre-Emmanuel Gerard, presented the key issues of BIOMUNEX PHARMACEUTICALS. Very happy to share today this excellente news for the development of #Biomunex. For more than 5 years, with one of our key Expert-in-Residence, St\u00e9phane MILOT, with Lo\u00efc MOULARD also for a few months, &hellip; <a href=\"https:\/\/blog.lallianse.com\/index.php\/en\/success-story-biomunex-pharmaceuticals-2\/\" class=\"more-link\">Continuer la lecture<span class=\"screen-reader-text\"> de &laquo;&nbsp;Success story : Biomunex Pharmaceuticals&nbsp;&raquo;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"advanced_seo_description":"","jetpack_seo_html_title":"","jetpack_seo_noindex":false,"jetpack_post_was_ever_published":false,"_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"footnotes":"","_jetpack_memberships_contains_paid_content":false},"categories":[246,240],"tags":[],"jetpack_sharing_enabled":true,"jetpack_featured_media_url":"","jetpack-related-posts":[],"_links":{"self":[{"href":"https:\/\/blog.lallianse.com\/index.php\/wp-json\/wp\/v2\/posts\/4207"}],"collection":[{"href":"https:\/\/blog.lallianse.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/blog.lallianse.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/blog.lallianse.com\/index.php\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/blog.lallianse.com\/index.php\/wp-json\/wp\/v2\/comments?post=4207"}],"version-history":[{"count":1,"href":"https:\/\/blog.lallianse.com\/index.php\/wp-json\/wp\/v2\/posts\/4207\/revisions"}],"predecessor-version":[{"id":4209,"href":"https:\/\/blog.lallianse.com\/index.php\/wp-json\/wp\/v2\/posts\/4207\/revisions\/4209"}],"wp:attachment":[{"href":"https:\/\/blog.lallianse.com\/index.php\/wp-json\/wp\/v2\/media?parent=4207"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/blog.lallianse.com\/index.php\/wp-json\/wp\/v2\/categories?post=4207"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/blog.lallianse.com\/index.php\/wp-json\/wp\/v2\/tags?post=4207"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}